Galmed Pharmaceuticals Ltd. EOCN
3.63
0.01
0.28%
as of 25 Sep
- Market cap
- $3.8M
- P/E
- 0.0×
Follow EOCN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
P/S ratio |
0.00 | 108.42 | 60.81 | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
P/Operating CF |
(14.62) | (47.36) | (55.08) | — | — | — | — | — | — | — |
P/B ratio |
3.73 | 7.45 | 1.41 | — | — | — | — | — | — | — |
Price to Tangible BV |
3.73 | 7.45 | 1.41 | — | — | — | — | — | — | — |
EV/Sales |
0.00 | 90.91 | 19.53 | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
EV/Operating CF |
(2.13) | (8.17) | (4.41) | — | — | — | — | — | — | — |
EV/FCF |
(2.13) | (8.17) | (4.37) | — | — | — | — | — | — | — |
Quick Ratio |
3.44 | 4.98 | 31.17 | 6.99 | 5.99 | 6.13 | 4.76 | 3.99 | 5.81 | 4.04 |
Current Ratio |
3.44 | 4.98 | 33.41 | 11.02 | 6.47 | 6.13 | 4.76 | 4.81 | 7.42 | 6.55 |
Net Debt/EBITDA |
0.93 | 1.57 | 8.03 | 2.11 | 1.56 | 1.06 | 0.79 | 1.41 | 1.92 | 1.31 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.46% | 0.41% | 0.63% | 0.27% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.06 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.72 | 0.98 | 0.92 | 0.73 | 0.91 | 1.01 | 1.04 | 0.89 | 0.78 | 0.61 |
Capex/Depreciation |
(0.02) | (0.05) | (0.37) | 0.17 | (0.34) | (0.07) | (0.12) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (103.94%) | (91.54%) | (19.01%) | (25.94%) | (50.47%) | (86.98%) | (81.36%) | (50.63%) | (49.77%) | (64.21%) | |
| (83.28%) | (68.15%) | (17.88%) | (24.40%) | (44.43%) | (72.97%) | (67.21%) | (41.65%) | (42.80%) | (55.53%) | |
ROIC |
0.00% | 0.00% | (177.49%) | (62.05%) | 0.00% | 0.00% | 0.00% | (138.82%) | (89.77%) | (114.43%) |
Return on Tangible Assets |
(142.81%) | (77.87%) | (11.21%) | (29.37%) | (65.43%) | (107.08%) | (152.13%) | (65.38%) | (53.88%) | (65.32%) |
Average Days of Receivables |
221.97 | 52.14 | 39.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
3,055.89% | 889.40% | 407.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
659.10% | 350.14% | 217.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
348.61% | 128.48% | 87.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.25 | 0.13 | 0.71 | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Earnings Yield |
(41.04%) | (10.44%) | (8.49%) | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(29.38%) | (10.27%) | (7.35%) | — | — | — | — | — | — | — |
Revenue per Share |
59.11 | 124.71 | 161.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1,535.32) | (1,387.01) | (716.11) | (1,016.12) | (1,776.15) | (1,923.51) | (1,057.20) | (213.09) | (50.52) | (11.72) |
Capex per Share |
(0.51) | (1.38) | (7.14) | (0.82) | (2.97) | (0.64) | (0.23) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1,535.82) | (1,388.39) | (723.25) | (1,016.94) | (1,779.12) | (1,924.15) | (1,057.43) | (213.09) | (50.52) | (11.72) |
Cash per Share |
1,955.44 | 2,183.56 | 6,676.27 | 3,242.52 | 3,188.65 | 2,042.63 | 794.23 | 364.79 | 102.71 | 20.66 |
Shareholders Equity per Share |
1,401.90 | 1,815.52 | 6,975.71 | 4,751.90 | 2,983.31 | 1,783.45 | 767.03 | 481.91 | 140.27 | 29.29 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1,401.90 | 1,815.52 | 6,975.71 | 4,751.90 | 2,983.31 | 1,783.45 | 767.03 | 481.91 | 140.27 | 29.29 |
Free Cash Flow |
(12.13) | (12.08) | (9.11) | (14.95) | (26.33) | (32.90) | (18.50) | (6.14) | (5.88) | (6.31) |
Working Capital |
11.15 | 15.30 | 87.70 | 69.50 | 43.80 | 30.18 | 11.63 | 10.49 | 13.95 | 15.78 |
Capital Expenditures |
0.00 | (0.01) | (0.09) | (0.01) | (0.04) | (0.01) | 0.00 | — | — | — |
Net Current Asset Value |
10.36 | 15.30 | 87.70 | 69.14 | 43.58 | 29.95 | 11.59 | 10.49 | 13.95 | 15.78 |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Capex to Sales |
0.01 | 0.01 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Net Profit Margin |
(3,630.19%) | (1,133.55%) | (483.61%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.30 | 0.53 | 1.25 | (0.41) | 0.73 | 1.12 | 0.29 | 0.60 | 0.00 | 0.00 |
Cash ROIC |
(48.44%) | (36.09%) | (5.36%) | (12.82%) | (28.90%) | (50.32%) | (68.02%) | (25.51%) | (20.79%) | (23.46%) |
Accounts Receivable Turnover |
1.41 | 4.94 | 10.93 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.33 | 0.22 | 0.19 | 0.52 | 0.82 | 0.97 | 0.98 | 0.65 | 0.58 | 0.51 |
Average Payables |
2.69 | 2.70 | 2.05 | 3.91 | 6.52 | 5.96 | 3.72 | 2.22 | 1.59 | 1.66 |
Average Assets |
20.36 | 18.05 | 55.12 | 83.87 | 64.76 | 44.49 | 26.58 | 16.60 | 17.56 | 18.56 |
Average Common Equity |
16.31 | 13.44 | 51.84 | 78.87 | 57.00 | 37.33 | 21.96 | 13.65 | 15.10 | 16.05 |
Columns are period end dates